Could Vir Biotechnology Be a Millionaire Maker Stock?
Vir Biotechnology (NASDAQ: VIR) may be weeks away from commercializing its very first product. The clinical-stage biotech company and partner GlaxoSmithKline late last month requested Emergency Use Authorization (EUA) for their investigational COVID-19 treatment. In more good news, GlaxoSmithKline recently expanded its collaboration with Vir to include the development of potential treatments for respiratory viruses including influenza.